Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

Pemetrexed and LBH589 in Previously-Treated Patients With Advanced Non-Small Cell Lung Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Jul 2015

At a glance

  • Drugs Panobinostat (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Jul 2015 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
    • 16 Sep 2009 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top